A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring

BACKGROUND: Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and safety. Therapeutic drug monitoring (TDM) can benefit patients’ outcomes from a biologic therapy when the latter has a defined therapeutic window. A clinically relevant therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleisher, Brett, Ait-Oudhia, Sihem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749565/
https://www.ncbi.nlm.nih.gov/pubmed/29343970
http://dx.doi.org/10.2147/OTT.S153056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749565/
https://www.ncbi.nlm.nih.gov/pubmed/29343970
http://dx.doi.org/10.2147/OTT.S153056

Ejemplares similares